Acetylsalicylic acid reduces niacin extended-release-induced flushing in patients with dyslipidemia

American Journal of Cardiovascular Drugs

Volumn 9, Issue 2, 2009, Pages 69-79

  Thakkar, Roopal B ^a   Kashyap, Moti L ^b,c   Lewin, Andrew J ^d   Krause, Scott L ^a   Jiang, Ping ^a   Padley, Robert J ^a  

^a ABBOTT LABORATORIES   (United States)

^b VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NATIONAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; NICOTINIC ACID; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG WITHDRAWAL; DYSLIPIDEMIA; ERYTHEMA; FEMALE; FLUSHING; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ADMINISTRATION, ORAL; ADULT; AGED; ANTILIPEMIC AGENTS; ASPIRIN; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FEMALE; FLUSHING; HUMANS; MALE; MIDDLE AGED; NIACIN; VASODILATOR AGENTS;

EID: 63849130311     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03256578     Document Type: Article

References (29)

1. Gille A, Bodor ET, AhmedK, et al. Nicotinic acid: pharmacological effects and mechanisms of action. Annu Rev Pharmacol Toxicol 2008; 48: 79-106
2. McKenney J. New perspectives on the use of niacin in the treatment of lipid disorders. Arch Intern Med 2004; 164 (7): 697-705
3. Ganji SH, Zhang LH, Kamanna VS, et al. Effect of niacin on lipoproteins and atherosclerosis. Future Lipidol 2006; 1 (5): 549-57
4. Clofibrate and niacin in coronary heart disease. JAMA 1975; 231 (4): 360-81
5. Vogt A, Kassner U, Hostalek U, et al. Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study. Vasc Health Risk Manag 2007; 3 (4): 467-79
6. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345 (22): 1583-92
7. Canner PL, Berge KG,WengerNK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8 (6): 1245-55
8. Oberwittler H, Baccara-DinetM. Clinical evidence for use of acetyl salicylic acid in control of flushing related to nicotinic acid treatment. Int J Clin Pract 2006; 60 (6): 707-15
9. ® (niacin) tablet ER [prescribing information]. North Chicago (IL):Abbott Laboratories, 2007
10. Whelan AM, Price SO, Fowler S, et al. The effect of aspirin on niacin-induced cutaneous reactions. J Fam Pract 1992; 34: 165-8
11. Jay RH, Dickson AC, Betteridge DJ. Effects of aspirin upon the flushing reaction induced by niceritrol. Br J Clin Pharmacol 1990; 29 (1): 120-2
12. Jungnickel PW, Maloley PA, Vander Tuin EL, et al. Effect of two aspirin pretreatment regimens on niacin-induced cutaneous reactions. J Gen Intern Med 1997; 12 (10): 591-6
13. Dunn RT, Ford MA,Rindone J, et al.Low-dose aspirin and ibuprofen reduce the cutaneous reactions following niacin administration. Am J Ther 1995; 2: 478-80
14. Wilkin JK, Wilkin O, Kapp R, et al.Aspirin blocks nicotinic acid-induced flushing. Clin Pharmacol Ther 1982; 31 (4): 478-82
15. Meyers CD, Liu P, Kamanna VS, et al. Nicotinic acid induces secretion of prostaglandin D2 in humanmacrophages: an in vitro model of the niacin flush. Atherosclerosis 2007; 192 (2): 253-8
16. Cefali EA, Simmons PD, Stanek EJ, et al.Aspirin reduces cutaneous flushing after administration of an optimized extended-release niacin formulation. Int J Clin Pharmacol Ther 2007; 45 (2): 78-88
17. ®): psychometric properties of a new measure assessing flushing symptoms and clinical impact of niacin therapy. Clin Drug Invest 2009; 29 (4): 215-29
18. ®-induced flushing in subjects with dyslipidemia (ASA EFFECTS) [ClinicalTrials.gov identifier: NCT00626392]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www. clinicaltrials.gov [Accessed 2009 Mar 6]
19. Turenne SD, Seeman M, Ross BM. An animal model of nicotinic-acid-induced vasodilation: effect of haloperidol, caffeine and nicotine upon nicotinic acid response. Schizophr Res 2001; 50: 191-7
20. Papaliodis D, Boucher W, Kempuraj D, et al. The flavonoid luteolin inhibits niacin-induced flush. Br J Pharmacol 2008; 153: 1382-7
21. 2 from mast cells and serotonin from platelets: evidence from human cells in vitro and an animal model. J Pharmacol Exp Therap 2008; 327: 665-72
22. Benyo Z, Gille A, Bennett CL, et al. Nicotinic acid-induced flushing ismediated by activation of epidermal langerhans cells. Mol Pharmacol 2006; 70 (6): 1844-9
23. BallantyneCM,DavidsonMH,McKenney J, et al.Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatinmonotherapy in patients with increased non-HDLcholesterol (from the SEACOAST I study). Am J Cardiol 2008; 101 (10): 1428-36
24. Guyton JR, Goldberg AC, Kreisberg RA, et al. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol 1998; 82 (6): 737-43
25. Karas RH, Kashyap ML, Knopp RH, et al. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study. Am J Cardiovasc Drugs 2008; 8 (2): 69-81
26. Paolini JF, Mitchel YB, Reyes R, et al. Effects of laropiprant on nicotinic acidinduced flushing in patients with dyslipidemia. Am J Cardiol 2008; 101 (5): 625-30
27. Lai E,DeLepeleire I, Crumley TM, et al. Suppression of niacin-induced vasodilation with an antagonist to prostaglandinD2 receptor subtype 1. Clin Pharmacol Ther 2007; 81 (6): 849-57
28. European Medicines Agency. Evaluation of Medicines for Human Use CHMP assessment report for Tredaptive [EMEA/348364/2008]. London: EMEA, 2008
29. Dishy V, Liu F, Ebel D, et al. Effects of aspirinwhen added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptoms. J Clin Pharmacol. Epub 2009 Feb 26